Evusheld Survey: New treatment to prevent COVID-19 infection in people with poor immune systems
Do you have scleroderma and have a weakened immune system? Would you like to have your say on whether a treatment which can prevent COVID-19 infection is made available to those who have poor immune responses in response to COVID-19 vaccination? Complete our short survey to inform our response to a NICE consultation on whether this treatment should be authorised for use.
Do you have Scleroderma?
Do you have a weakened immune system due to the medicines you are taking to control your scleroderma?
Are you worried about contracting COVID-19 despite being vaccinated?
A new preventative treatment has been developed which can protect those with weakened immune systems from COVID-19 infection. The treatment is comprised of two injections given one after the other into a muscle (intramuscular injection) by a doctor or other qualified healthcare professional. Protection lasts for six months. It cannot be used to prevent infection in those who have recently been exposed to the virus through coming into close contact with an infected person.
Before it can be used within the NHS, the treatment requires market authorisation via the National Institute of Health and Clinical Excellence (NICE). As part of this process, NICE are carrying out an assessment of the therapy’s clinical and cost effectiveness and are keen to gather the views of various stakeholders such as professional bodies, NHS commissioning organisations, and patient groups. NICE wants to understand your condition and how the threat of COVID-19 affects you.
SRUK, as part of our role in championing access to more effective treatments, is aware of the need to actively contribute to this process. We are inviting patients with scleroderma who are taking immunosuppressive medications to manage their condition to help inform our response to this important consultation by participating in our short survey.
Our questionnaire should take no more than 10 minutes of your time!
Survey responses are anonymous, the data will be viewed by SRUK to inform our report to NICE.
If you have any questions relating to the survey, please contact info@sruk.co.uk.
LINK TO QUESTIONNAIRE: https://www.surveymonkey.co.uk/r/M8YD9RS